COCH Form 4 reports purchase transactions

Patel Mona Chetan reported open-market purchase transactions in a Form 4 filing for COCH.

Rhea-AI Filing Summary

Patel Mona Chetan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 812,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 187,500 shares.

Insider Trade Summary

Net Buyer: 812,500 shares

Net Buy 5 txns

Insider Patel Mona Chetan

Role Director

Bought 812,500 shs ($125K)

Type	Security	Shares	Price	Value
Purchase	Warrant (right to buy)	187,500	$0.00	$0.00
Purchase	Warrant (right to buy)	312,500	$0.00	$0.00
Purchase	Class A Common Stock	312,500	$0.40	$125K
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Warrant (right to buy) — 500,000 contracts (Direct); Class A Common Stock — 332,500 shares (Direct); Stock Option (right to buy) — 50,000 contracts (Direct)

Footnotes (4)

1. F1. Options to purchase 6,250 shares vest on 10/15/2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
2. F2. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
3. F3. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
4. F4. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Envoy Medical (COCH) report for Mona Chetan Patel on February 12, 2026?

Envoy Medical reported that director Mona Chetan Patel bought 312,500 Class A shares at $0.40 each and acquired two warrant blocks for 187,500 and 312,500 shares, both with $0.40 exercise prices and direct ownership, on February 12, 2026.

How many Envoy Medical (COCH) shares does Mona Chetan Patel own after the reported transactions?

After the transaction, Mona Chetan Patel directly owns 332,500 Class A common shares. She also holds warrants covering a total of 500,000 additional shares and two stock option positions of 25,000 shares each, providing further potential equity exposure if exercised.

What are the key terms of the Envoy Medical (COCH) warrants acquired by Mona Chetan Patel?

Patel acquired Series A-1 and Series A-2 warrants with a $0.40 exercise price, covering 187,500 and 312,500 shares. They become exercisable only after shareholder approval of the underlying share issuance and have expirations tied to specific FDA milestones for the Acclaim CI Device.

How do the FDA milestones affect Mona Chetan Patel’s Envoy Medical (COCH) warrants?

The Series A-1 warrants expire two years from initial exercise or 30 days after Envoy Medical announces submission of a Premarket Approval Application for the Acclaim CI Device. Series A-2 warrants expire five years from initial exercise or 30 days after announced FDA approval.

What are the vesting terms of Mona Chetan Patel’s Envoy Medical (COCH) stock options?

One stock option grant to purchase 25,000 shares vests with 6,250 shares on October 15, 2024, and the remaining 18,750 shares vest in equal monthly installments over 36 months on the 15th of each month, subject to standard option conditions.

Is Mona Chetan Patel’s Envoy Medical (COCH) ownership direct or through another entity?

The filing classifies all reported holdings and transactions, including common shares, warrants, and stock options, as direct ownership. No footnotes indicate that these securities are held through a separate trust, partnership, or other indirect ownership vehicle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:51 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Mona Chetan

(Last) (First) (Middle)

C/O 4875 WHITE BEAR PARKWAY

(Street)

WHITE BEAR LAKE MN 55110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Envoy Medical, Inc. [ COCH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/12/2026		P		312,500	A	$0.4	332,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.4							(1)	10/15/2033	Class A Common Stock	25,000		25,000	D
Stock Option (right to buy)	$0.813							05/01/2026	12/03/2035	Class A Common Stock	25,000		25,000	D
Warrant (right to buy)	$0.4	02/12/2026		P		187,500		(2)	(3)	Class A Common Stock	187,500	$0	187,500	D
Warrant (right to buy)	$0.4	02/12/2026		P		312,500		(2)	(4)	Class A Common Stock	312,500	$0	312,500	D

Explanation of Responses:

1. Options to purchase 6,250 shares vest on 10/15/2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

2. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

3. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

4. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

	/s/ Andrew Nick as Attorney-in-Fact for Mona Chetan Patel pursuant to Power of Attorney previously filed.	02/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.